Eleven strains of Ttypanosoma cruzi were isolated from patients with Chagas disease in central Brazil by xenodiagnosis and inoculation into newborn mice. Biological characterization and isoenzyme analysis showed that 6 strains were type II (zymodeme 2) and 5 were type III (zymodeme 1). Patients were treated with benznidazole or benznidazole plus nifurtimox. Mice infected with each isolated strain were treated for comparison with the results obtained in the respective patient. Evaluation of cure of the patients was based on the indirect immunofluorescence test, complement fixation reaction and xenodiagnosis. For the mice, haemoculture, indirect immunofluorescence testing, xenodiagnosis and inoculation of blood into newborn mice were used. Tests were performed 3-6 months after the end of treatment. The cure rate was 66-100% in mice infected with type II strains and O-9% in those infected with type III strains. The correlation between treatment results in patients and mice was 8 1.8% (9 of 11 cases). Type II strains were more susceptible to treatment, in contrast to type III strains which yielded the majority of therapeutic failures.
Introduction
pared, in the hope that this would help to clarify the role Treatment of patients with acute and chronic Chagas of parasite strain in susceptibility and resistance to drug disease with the drugs in current clinical use (benznida-treatment. zole and nifurtimox) has yielded disparate results (BOAI-NAIN & RAN, 1979; PRATA et al., 1975) . Discrepancies Materials and Methods are even greater when therapeutic trials from different
The area in central Brazil from which the 11 strains of geographical areas are compared. CERISOLA et al. (1974) T. cruzi were isolated has been described by LUQUETTI et in Argentina claimed an 81% cure rate with nifurtimox in al. (1986) . Six cases were from Montalvania, north-west acute infections. In Brazil the reported rates with the Minas Gerais state, 4 came from Carinhanha, Bahia and same drug were 38.4% (RASH & FERREIRA, 1971 ) and one from A. Dourados, close to the eastern border of 33.3% (CANCADO, 1985) . With benznidazole, LEDESMA Goias state. (1988) obtained 80% cure in Argentina, while in Brazil the rates were 53.8% (CANCADO, 1985) and 51.3% (RASSI, 1982) .
One of the factors contributing to these different results could be the parasite strain together with the predominance of certain stable strains in some geographical areas. Experimentally, there is evidence that parasite strain is an important factor influencing the results obtained with benznidazole and nifurtimox. Differences in susceptibility to these drugs correlate well with the biological characteristics of parasite strains .
The present investigation was an attempt to compare clinical and experimental observations. Several strains of Ttypanosoma cnrzi were isolated from patients living in central Brazil and were characterized to strain types according to established criteria (ANDRADE, 1985; WHO, 1986) . Results of treatment in the patient and in mice infected with the corresponding T. cruzi strain were com-Description of clinical cases. General clinical data are given in the Table. Nine patients had acute Chagas disease (6 females and 3 males) and 2 had chronic infections (indeterminate form). Parasites were detected by direct examination of peripheral blood in all acute cases and by xenodiagnosis in the chronic cases.
CZinical chemotherapy. Nine patients were treated solely with benznidazole. Two other patients received nifurtimox either preceding (case 2) or following (case 3) treatment with benznidazole. Benznidazole (N-benzyl-2-(2 nitro-imidazol-1-yl)acetamide) was given orally in doses of 5-10 mgikg body weight/d divided into 2 or 3 doses, for 60 d. Nifurtimox (tetrahydro-3-methyl-4-(nitrofurfuryldieneamino-1, 4 thiazine-1 , l-dioxide) was given orally in doses of 8-8.7 mg/kg body weight/d for 60 or 75 d (see Table) .
Criteria of cure. Evaluation of therapeutic results was based on xenodiagnosis, indirect immunofluorescence (IIFT) and complement fixation reactions (CFR). Pa-tients were considered cured when both serological tests remained persistently negative and xenodiagnosis, performed monthly and repeated 25 or more times, was consistently negative. Xenodiagnosis was performed with 40 third-stage nymphs of Triatominae, which were examined 30 and 60 d after blood feeding.
ExPerimental procedures. T. cruzi was isolated from reduviih nymphs' which had been used for xenodiagnosis and the strains were characterized by morpho-biological features (ANDRADE, 1985) and isoenzyme electrophoretic oatterns (MILES, 1980; ANDRADE et al., 1983) . Briefly, morpho-&ologic>l chaiacterization con&ted of the o& servation of parasitaemia curves, morphology of blood forms of the parasite, virulence, tissue tropism, and histopathology during experimental infectlons of mice. Isoenzyme patterns were determined from extracts of Darasites cultured in Warren's medium. The following knzymes were studied: aspartate aminotransferase (E.C.2.6.1.1.
ASAT). alanine aminotransferase (~.~.2.6.1.2:, ALAT), phosphoglucomutase (E.C.2.7.5. l., PGM) and glucose phosphate isomerase (E.C.5.3.1.9.,GPI).
Experimental chemotherapy. Each isolated strain was inoculated to a group of 70 mice each weighing lo-12 g. Each mouse received 1 x lo5 blood forms. Thirty mice were treated with benznidazole, 30 with nifurtimox, and 10 were left as untreated controls. Dosage schedules for the mice were based upon that used by HABERKORN & GONNERT (1972) , whd established the equivalence between doses of 15 or 10 maike: bodv weight for adult men and doses of 180 or 130~mg/kg bod'jr weight for mice. An initial daily dose of 200 mgikg of nifurtimox was given for 4 d, followed by 50 mg/kg for 90 d. Benznidazole was given on 5 d per week, at 100 mgikg body weight, for 90 d, according to RICHLE & RAAFLALJB (1980) . Criteria of cure. Xenodiagnosis with 5th stage R. prolixus nymihs, subinocula<on of blood into-newborn mice (0.1 ml, intraperitoneally) and haemoculture were performed 3-6 months after treatment. The same tests were made on the control mice. IIFT was nerformed with T. cruzi culture forms as antigen and anti-mouse fluorescein-conjugated y-globulin (dilution 1:80). Titres > 1: 10 were considered to be positive.
Results

Experimental results
Six of the isolated T. cruzi strains belonged to type II (zymodeme 2) and 5 to type III (zymodeme 1) (Table) . Mice infected with most type II strains had a cure rate of 66100% when treated with benznidazole and nifurtimox (Table) . One strain (b-MONT), from a previously treated patient, was an exceptional therapeutic failure. Responses of the type III strains to treatment were poor with both drugs, the cure rate being nil for 4 strains and only 5-9% for the other strains (~-MONT) (Table) .
Assessment of cure was based on the parasitological tests, because the IIFT remained positive with all animals.
Clinical results
Seven of the 11 patients treated with benznidazole were considered cured, with both xenodiagnosis and serological tests consistently negative. Therapeutic failures were observed in 4 patients, 2 of whom were treated with both drugs (Table) .
Comparison of clinical and experimental results
The results of clinical and experimental chemotherapy were in agreement in 9 of the 11 cases (82%). Five of the 6 patients harbouring type II strains were cured, and mice infected with type II strains had a high cure rate. *Four species were used? according to availability: Rhodniusprolixus, Triatoma braslllensis, T. infestans and Dipetalogaster maxima.
Therapeutic failures were observed in 3 of 5 patients infected with type III strains (60%), and mice infected with type III strains exhibited poor therapeutic responses.
Discussion
Morpho-biological classification into strain types as proposed by ANDRADE (1985) and zymodeme classification according to MILES et al. (1980) were in good agreement. Human infections with parasites belonging to both zymodemes 1 and 2 have already been reported in central Brazil by LUQUETTI et al. (1986) .
Although the number of human cases in our series was rather small to permit definitive conclusions, the extent of agreement of therapeutic results in humans and mice was impressive. Previous experiments in mice have already demonstrated that type II strains of T. cruzi are more susceptible to drugs than type III strains, which are usually quite resistant . Previous treatment is known to increase the resistance of a strain, and this may explain the exceptional resistance of the type II strain infecting case 2, the sole instance in this study of the parasites being isolated after the patient was treated. The 2 other instances of disagreement between clinical and experimental results are more difficult to explain. Patients no. 4 and no. 10 were cured, but the isolated strains (type III, zymodeme 1) exhibited resistance to both nifurtimox and benznidazole in experimental infections.
The persistence of positive serological test in parasitologically cured mice is not surprising. It has been observed before and is correlated with the prolonged storage of T. cruzi antigens in dendritic spleen cells (ANDRADE et al., 1991) .
The comparative therapeutic results in the 2 different host species strongly suggest that parasite strain is a key factor influencing chemotherapeutic outcome. Therefore, it is important to characterize a significant number of strains in a given geographical area and to test their susceptibility to anti-T. cruzi compounds, in order to increase the chance of successful treatment.
